Evidence map›Paper›PMID 30371196›Full record

ArticleJournal of the American Heart Association2018

Disruption of VEGF Mediated Flk-1 Signaling Leads to a Gradual Loss of Vessel Health and Cardiac Function During Myocardial Infarction: Potential Therapy With Pellino-1.

Mahesh Thirunavukkarasu, Vaithinathan Selvaraju, Mandip Joshi, Vladimir Coca-Soliz, Leonidas Tapias, IbnalWalid Saad, Craig Fournier, Aaftab Husain, Jacob Campbell, Siu-Pok Yee and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Cytochrome bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Article
  2. Article
  3. Atheroprotective Aspects of Heat Shock Proteins.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Mahesh Thirunavukkarasu1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Vaithinathan Selvaraju1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Mandip Joshi1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Vladimir Coca-Soliz1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Leonidas Tapias1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
IbnalWalid Saad1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Craig Fournier1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Aaftab Husain1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Jacob Campbell1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
Siu-Pok Yee4 Center for Mouse Genome Modification University of Connecticut Health Farmington CT.
Juan A Sanchez3 Stanley J. Dudrick Department of Surgery Saint Mary's Hospital Waterbury CT.
J Alexander Palesty3 Stanley J. Dudrick Department of Surgery Saint Mary's Hospital Waterbury CT.
David W McFadden2 Department of Surgery University of Connecticut Health Farmington CT.
Nilanjana Maulik1 Molecular Cardiology and Angiogenesis Laboratory University of Connecticut Health Farmington CT.
UConn Health · USUniversity of Saint Mary · USUniversity of Connecticut · US

Funding

Angiogenic Regulators in Ischemic DisordersR01GM112957 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MAULIK, NILANJANA · 2015 to 2018
$1.7M
NIGMS NIH HHS R01 GM112957
6 · The paper itself

Abstract

Background The present study demonstrates that the ubiquitin E3 ligase, Pellino-1 (Peli1), is an important angiogenic molecule under the control of vascular endothelial growth factor (VEGF) receptor 2/Flk-1. We have previously reported increased survivability of ischemic skin flap tissue by adenovirus carrying Peli1 (Ad-Peli1) gene therapy in Flk-1

Indexed as

AnimalsBlotting, WesternCells, CulturedDisease Models, AnimalGene Expression RegulationGenetic TherapyHumansImmunohistochemistryMiceMice, Inbred ICRMyocardial InfarctionMyocardiumNeovascularization, PhysiologicNuclear ProteinsPhosphorylationSignal TransductionNuclear ProteinsPELI1 protein, humanUbiquitin-Protein LigasesVascular Endothelial Growth Factor Receptor-2adenovirusanimal modelsgene therapygeneticsmyocardial infarctionmyocardial revascularization

Identifiers

PMID30371196
PMCPMC6222946
OpenAlexW2890707762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.